Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Between Bedside and Bench
  • Published:

Muscling in: Gene therapies for muscular dystrophy target RNA

Muscle diseases can take many forms, from the progressive muscle degeneration of dystrophies to the childhood cancer rhabdomyosarcoma. In 'Bench to Bedside', Joel R. Chamberlain and Jeffrey S. Chamberlain discuss studies using antisense oligonucleotides to treat Duchenne muscular dystrophy and myotonic dystrophy. In 'Bedside to Bench', Simone Hettmer and Amy J. Wagers examine the implications of clinical studies describing a type of rhabdomyosarcoma that resembles acute leukemia. The findings dovetail with other studies suggesting that some of these cancers might originate outside of muscle tissue and highlight the need for a better understanding of the cells that give rise to this condition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Exon-skipping strategies using antisense oligonucleotides.

References

  1. Arnett, A.L., Chamberlain, J.R. & Chamberlain, J.S. Curr. Opin. Genet. Dev. 19, 290–297 (2009).

    Article  CAS  Google Scholar 

  2. van Deutekom, J.C. et al. N. Engl. J. Med. 357, 2677–2686 (2007).

    Article  CAS  Google Scholar 

  3. Kinali, M. et al. Lancet Neurol. 8, 918–928 (2009).

    Article  CAS  Google Scholar 

  4. Wheeler, T.M. et al. Science 325, 336–339 (2009).

    Article  CAS  Google Scholar 

  5. Mann, C.J. et al. Proc. Natl. Acad. Sci. USA 98, 42–47 (2001).

    Article  CAS  Google Scholar 

  6. Alter, J. et al. Nat. Med. 12, 175–177 (2006).

    Article  CAS  Google Scholar 

  7. Yokota, T. et al. Ann. Neurol. 65, 667–676 (2009).

    Article  Google Scholar 

  8. Miller, J.W. et al. EMBO J. 19, 4439–4448 (2000).

    Article  CAS  Google Scholar 

  9. Liquori, C.L. et al. Science 293, 864–867 (2001).

    Article  CAS  Google Scholar 

  10. Margolis, J.M., Schoser, B.G., Moseley, M.L., Day, J.W. & Ranum, L.P. Hum. Mol. Genet. 15, 1808–1815 (2006).

    Article  CAS  Google Scholar 

  11. Li, L.B., Yu, Z., Teng, X. & Bonini, N.M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453, 1107–1111 (2008).

    Article  CAS  Google Scholar 

  12. Svasti, S., et al. RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. Proc. Natl. Acad. Sci. USA. 164, 1205–1210 (2009).

    Article  Google Scholar 

  13. Goyenvalle, A., Babbs, A., van Ommen, G.-J., Garcia, L. & Davies, K.E. Mol. Ther. 17, 1234–1240 (2009).

    Article  CAS  Google Scholar 

  14. Gregorevic, P. et al. Nat. Med. 10, 828–834 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Joel R Chamberlain or Jeffrey S Chamberlain.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chamberlain, J., Chamberlain, J. Muscling in: Gene therapies for muscular dystrophy target RNA. Nat Med 16, 170–171 (2010). https://doi.org/10.1038/nm0210-170

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0210-170

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer